PAREXEL Clinical Research Services, Corporate Vice President of Business Operations Luke VanHengel discusses his company’s comprehensive clinical research services, which range from First-in-Human through Phase IV and Post-marketing follow-through. PAREXEL has the regulatory expertise, clinical trial operations management, payer and market access planning, medical education and communications capabilities to see your journey through efficiently and effectively.
Clinical Research Services: another example of how PAREXEL is bringing it all together.
Boston, MA, February 10, 2015 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it has been recognized among top U.S. businesses in Training magazine’s annual “Training Top 125.” PAREXEL earned a place in the ranking this year for developing creative and effective employee learning and development initiatives for their global workforce.
“From traditional instructor-led settings to eLearning environments, PAREXEL provides best-in-class learning products and customized training programs to present employees with valuable career and job skills development,” said Albert Siu, Vice President, Learning and Development, PAREXEL. “In the highly complex and regulated drug development environment, having expertly trained employees around the globe is an essential element to help our clients simplify their journey toward bringing new drugs to market for patients.”
PAREXEL’s comprehensive learning and training programs encompass four primary learning domains including: company culture and strategy; functional competencies; leadership development; and professional development. The Company’s standardized instructional design model ensures training programs address the complexities of global clinical trial requirements today, with each program featuring a unique set of performance metrics to measure operational and training effectiveness across the learning disciplines.
“PAREXEL impressed us with its focus on delivering ‘the right training, to the right people, at the right time’ to ensure its employees are prepared to succeed in their jobs and careers,” said Lorri Freifeld, editor-in-chief, Training magazine. “The competition was fierce this year, and PAREXEL’s global learning and development initiatives earned it this well-deserved spot in our 2015 ranking.”
In addition to training employees, PAREXEL is committed to developing the future, global biopharmaceutical workforce with courses specifically tailored to meet the growing talent needs of the clinical development job market. Since 2001, the PAREXEL Academy has designed and implemented a wide-range of learning and performance programs tailored to enable clinical research management practices for learners outside of PAREXEL. The PAREXEL Academy has locations in the United States, Europe, and Asia.
For the last 15 years, Training magazine, the leading business publication for learning and development professionals, has issued its annual “Training Top 125,” which ranks companies’ excellence in employer-sponsored training and development programs. The ranking is based on myriad benchmarking statistics such as total training budget; percentage of payroll; number of training hours per employee program; goals, evaluation, measurement of outcomes and impact, and workplace surveys; hours of training per employee annually; and detailed formal programs.
Drug development today is more than a process. It's a journey. At PAREXEL, we are committed to making your journey our mission. To solving problems before they arise. To making the process smarter and more efficient. To being a true partner to our clients, in every sense. For over 30 years we have helped our clients get their new and innovative drug treatments into the hands that need them most by simplifying their journey to market. Today that means going above and beyond—at every step along the way.
Though we are well known for our clinical research services, our breadth of expertise encompasses the continuum of product development and commercialization, from early planning through regulatory and post-approval. We view each step as an opportunity to work smarter, more efficiently and more effectively. We don't fear complexity, we embrace it. This mindset, backed up by achievement, has also enabled us to do pioneering work in emerging fields like biosimilars. Work that is paving the way forward for our clients and the industry.
PAREXEL strives to be the premier provider to the biopharmaceutical and medical device industries for the development and commercialization of new medical therapies worldwide.
Headquartered near Boston, Massachusetts, PAREXEL operates in 82 locations in 51 countries around the world, and has 18,450 employees.
We provide the most comprehensive drug development capabilities of any CRO worldwide. Our global regulatory expertise, Phase I-IV clinical research services, integrated eClinical technologies, and advanced commercialization services all work together to move you through the development journey more smoothly and cost-effectively from beginning to end.
PAREXEL's mission is to combine the strength of our expertise, experience and innovation to advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease. – less